Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Five years of alcohol de-addiction services in a tertiary care general hospital.

Chandrasekaran R, Sivaprakash B, Chitraleka V.

Indian J Psychiatry. 2001 Jan;43(1):58-60.

2.

Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability.

Koch AL, Arfken CL, Schuster CR.

Drug Alcohol Depend. 2006 Jul 27;83(3):274-8. Epub 2006 Jan 18.

PMID:
16413146
3.

Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs.

Saxon AJ, McCarty D.

Pharmacol Ther. 2005 Oct;108(1):119-28. Review.

PMID:
16055196
4.

A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network.

Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, Brigham G, Harrer J, Reid M, Muir J, Buchan B, Orr D, Woody G, Krejci J, Ziedonis D; Buprenorphine Study Protocol Group.

Addiction. 2005 Aug;100(8):1090-100. Erratum in: Addiction. 2006 Sep;101(9):1374.

5.

Adoption of naltrexone to treat alcohol dependence.

Fuller BE, Rieckmann T, McCarty D, Smith KW, Levine H.

J Subst Abuse Treat. 2005 Apr;28(3):273-80.

PMID:
15857728
6.

Buprenorphine for the management of opioid withdrawal.

Gowing L, Ali R, White J.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD002025. Review. Update in: Cochrane Database Syst Rev. 2006;(2):CD002025.

PMID:
15495026
7.

Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.

Amass L, Ling W, Freese TE, Reiber C, Annon JJ, Cohen AJ, McCarty D, Reid MS, Brown LS, Clark C, Ziedonis DM, Krejci J, Stine S, Winhusen T, Brigham G, Babcock D, Muir JA, Buchan BJ, Horton T.

Am J Addict. 2004;13 Suppl 1:S42-66.

8.

Modeling the use of innovations in private treatment organizations: the role of absorptive capacity.

Knudsen HK, Roman PM.

J Subst Abuse Treat. 2004 Jan;26(1):353-61.

PMID:
14698799
9.

Understanding US addiction physicians' low rate of naltrexone prescription.

Mark TL, Kranzler HR, Song X.

Drug Alcohol Depend. 2003 Sep 10;71(3):219-28.

PMID:
12957340
10.

Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.

Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D; Buprenorphine/Naloxone Collaborative Study Group.

N Engl J Med. 2003 Sep 4;349(10):949-58.

11.

Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

Mattick RP, Breen C, Kimber J, Davoli M.

Cochrane Database Syst Rev. 2003;(2):CD002209. Review. Update in: Cochrane Database Syst Rev. 2009;(3):CD002209.

PMID:
12804430
12.

Physicians' opinions about medications to treat alcoholism.

Mark TL, Kranzler HR, Song X, Bransberger P, Poole VH, Crosse S.

Addiction. 2003 May;98(5):617-26.

PMID:
12751979
13.

Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence.

Bridge TP, Fudala PJ, Herbert S, Leiderman DB.

Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S79-85. Review.

PMID:
12738352
14.

The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic.

Walsh SL, Eissenberg T.

Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S13-27. Review.

PMID:
12738347
15.

From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States.

Jaffe JH, O'Keeffe C.

Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S3-11. Review.

PMID:
12738346
16.

Research to practice: adoption of naltrexone in alcoholism treatment.

Thomas CP, Wallack SS, Lee S, McCarty D, Swift R.

J Subst Abuse Treat. 2003 Jan;24(1):1-11.

PMID:
12646325
17.

A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal.

Lintzeris N, Bell J, Bammer G, Jolley DJ, Rushworth L.

Addiction. 2002 Nov;97(11):1395-404.

PMID:
12410780
18.

Clinical inquiries. How effective are pharmacologic agents for alcoholism?

Hunt RR.

J Fam Pract. 2002 Jun;51(6):577. Review. No abstract available.

PMID:
12100788
19.

Adoption and implementation of new technologies in substance abuse treatment.

Roman PM, Johnson JA.

J Subst Abuse Treat. 2002 Jun;22(4):211-8.

PMID:
12072165
20.

A conceptual framework for transferring research to practice.

Simpson DD.

J Subst Abuse Treat. 2002 Jun;22(4):171-82.

PMID:
12072162

Supplemental Content

Support Center